Filtered By:
Education: Study
Management: Centers for Disease Control and Prevention (CDC)
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

E-129 Trends in demographic and geographic disparities of stroke-related mortality in older adults in the United States from 1999 to 2020
Stroke is a leading cause of mortality and morbidity in the United States. Many risk factors are controversial, and their relative importance is not fully understood. Elucidating the association between demographic and geographic disparities and stroke-related mortality in older adults will guide policy to alleviate stroke burden. This retrospective cohort study characterizes stroke-related mortality among individuals aged 55 and older in the United States from January 1999 to December 2020 using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. Segmented regressio...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: McCandless, M., Powers, A., Baker, K., Strickland, A. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

5 Minutes To Better Heart Health
Americans are living through a blood pressure crisis. Maybe you, or someone you love, is one of them… In the United States, 65% of adults over the age of 50 are living with above-normal blood pressure – increasing their risk of heart attack and stroke. And that’s just the tip of the iceberg. Because high blood pressure can also put you at higher risk for developing dementia later in life.1 Of course, Big Pharma doesn’t see this as a big problem. They know they can use this crisis to sell more drugs… drugs that never fail to do more harm than good. But a new study reveals how you can lower blood pressure – a...
Source: Al Sears, MD Natural Remedies - December 23, 2022 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Health Heart Health Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

This County Tried to Ensure Racial Equity in COVID-19 Vaccinations. The State Said No
It takes about eight minutes to try and save a life. Or at least that’s how long it takes a volunteer with a tablet, standing in the parking lot at the T.R. Hoover Community Development center in South Dallas on a bitterly cold February morning. During the pandemic, the small nonprofit situated in the neighborhood that developers in the 1920s dubbed “the Ideal community” has taken on an ever evolving list of roles. It’s a job-search center. It’s a drive-through food pantry. And, of late, T.R. Hoover is an in-person coronavirus vaccine registration site aimed at helping Ideal’s mainly Bla...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 feature Source Type: news

When a Texas County Tried to Ensure Racial Equity in COVID-19 Vaccinations, It Didn ’t Go as Planned
It takes about eight minutes to try and save a life. Or at least that’s how long it takes a volunteer with a tablet, standing in the parking lot at the T.R. Hoover Community Development center in South Dallas on a bitterly cold February morning. During the pandemic, the small nonprofit situated in the neighborhood that developers in the 1920s dubbed “the Ideal community” has taken on an ever evolving list of roles. It’s a job-search center. It’s a drive-through food pantry. And, of late, T.R. Hoover is an in-person coronavirus vaccine registration site aimed at helping Ideal’s mainly Bla...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Authors: Janell Ross/Dallas Tags: Uncategorized COVID-19 feature Source Type: news

Approaches in Prehospital Sepsis Screening
Discussion In the United States, sepsis is one of the leading causes of death, which requires timely identification and proper treatment (CDC, 2019; Guerra et al., 2020; Polito et al., 2015). Based upon a review of literature conducted from 2014 to 2018, the primary investigators could locate five prehospital EMS screening tools to assist EMS providers in identifying at-risk sepsis patients. The researchers explored how the modified SIRS and qSOFA scoring systems were used in hospital settings in addition to these five prehospital EMS screening tools. The Bas 90-30-90, Guerra, PRESEP, PRESS, and Robson tools have ove...
Source: JEMS Operations - January 5, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives Patient Care EMS EMT Paramedic Prehospital Sepsis Source Type: news

UCLA researchers study genetics ’ role in COVID-19 susceptibility, severity
“One of the most troubling things about COVID-19 is that we have a limited ability to predict how sick a specific individual will get,” said Dr. Daniel Geschwind.Geschwind is the MacDonald Distinguished Professor in Human Genetics at theDavid Geffen School of Medicine at UCLA and a member of theEli and Edythe Broad Center of  Regenerative Medicine and Stem Cell Research at UCLA. And he ’s part of a team of UCLA scientists conducting research to learn why certain people get sick from the virus that causes COVID-19 — and why others don’t.Millions of people around the world have been infected with SARS-CoV-2, the v...
Source: UCLA Newsroom: Health Sciences - October 26, 2020 Category: Universities & Medical Training Source Type: news

CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment
IRVINE, CA – September 9, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies* today announced that it has launched CERENOVUS Stroke Solutions™, which includes a suite of three devices designed to aid physicians in clot removal procedures. The announcement was made during the virtual European Society of Minimally Invasive Neurological Therapy (ESMINT).Strokes are the second leading cause of death globally, and account for an estimated 140,000 deaths in the United States each year.[i],[ii] Over half of stroke survivors become chronically disabled placing an estimated $34 billion economic burden o...
Source: Johnson and Johnson - September 9, 2020 Category: Pharmaceuticals Source Type: news

The Difficulty Of Counting the COVID-19 Pandemic ’s Full Death Toll
Sara Wittner had seemingly gotten her life back under control. After a December relapse in her battle with drug addiction, the 32-year-old completed a 30-day detox program and started taking a monthly injection to block her cravings for opioids. She was engaged to be married, working for a local health advocacy group in Colorado, and counseling others about drug addiction. Then the COVID-19 pandemic hit. The virus knocked down all the supports she had carefully built around her: no more in-person Narcotics Anonymous meetings, no talks over coffee with trusted friends or her addiction recovery sponsor. As the virus stressed...
Source: TIME: Health - June 22, 2020 Category: Consumer Health News Authors: Markian Hawryluk / Kaiser Health News Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson Launches Heartline ™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The study is designed to explore if the Heartline™ Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline™ Study, individuals must be age 65 or older...
Source: Johnson and Johnson - February 25, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news